Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The transient ischemic attack (TIA) market is a significant aspect of healthcare, focusing on the prevention, diagnosis, and treatment of temporary disruptions in blood flow to the brain. Often referred to as "mini-strokes," TIAs are warning signs of potential strokes and require prompt medical attention to prevent more severe neurological damage. This market segment is vital due to the serious consequences associated with TIAs, including an increased risk of subsequent strokes, cognitive impairment, and disability. As awareness of TIAs grows among healthcare professionals and the general population, there is a growing demand for effective strategies to identify and manage these transient events.
Key players in the TIA market include pharmaceutical companies, medical device manufacturers, diagnostic imaging providers, and healthcare facilities specializing in stroke care. Pharmaceutical interventions play a crucial role in preventing recurrent TIAs and strokes by targeting underlying risk factors such as hypertension, hyperlipidemia, and atrial fibrillation. Medications such as antiplatelet agents (e.g., aspirin, clopidogrel), anticoagulants, statins, and blood pressure-lowering drugs are commonly prescribed to reduce the risk of clot formation, improve blood flow, and stabilize atherosclerotic plaques in the arteries supplying the brain.
In addition to pharmaceutical interventions, medical devices and diagnostic tools play a crucial role in the TIA market by enabling healthcare providers to accurately diagnose TIAs, assess stroke risk, and guide treatment decisions. Advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and carotid ultrasound are used to visualize blood flow in the brain and identify potential causes of TIA symptoms, such as arterial stenosis or emboli. These imaging techniques help clinicians differentiate between TIAs and other neurological conditions, allowing for timely intervention and risk stratification.
Another important aspect of the TIA market is rehabilitation and secondary prevention strategies aimed at reducing the risk of recurrent TIAs and strokes. Rehabilitation programs may include physical therapy, occupational therapy, speech therapy, and cognitive rehabilitation to address deficits in motor function, activities of daily living, communication, and cognitive abilities. Lifestyle modifications, such as smoking cessation, dietary changes, exercise, and weight management, are also emphasized to control modifiable risk factors and improve overall cardiovascular health.
The TIA market is influenced by various factors, including demographic trends, epidemiological patterns, healthcare policies, and technological advancements. With an aging population and a growing prevalence of risk factors such as obesity, diabetes, and hypertension, the burden of TIAs and strokes is expected to increase globally. As a result, there is a growing emphasis on preventive measures, early detection, and comprehensive stroke care to reduce the societal and economic impact of these neurological events.
Technological innovations are driving advancements in the diagnosis and treatment of TIAs, with emerging trends such as telemedicine, artificial intelligence (AI), and remote monitoring showing promise in improving access to care and optimizing treatment outcomes. Telestroke programs enable remote consultation and decision-making between stroke specialists and healthcare providers in underserved areas, facilitating timely administration of thrombolytic therapy and other acute interventions. AI algorithms are being developed to analyze medical imaging data and assist radiologists in detecting subtle abnormalities indicative of TIAs, allowing for faster and more accurate diagnoses.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
Transient Ischemic Attack Market Highlights:
Transient Ischemic Attack Market Overview
The transient ischemic attack market is anticipated to reach USD 2026.6 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030
Transient ischemic stroke is also known as a mini-stroke. It leads to temporary blockage of blood flow to the brain. As it does not cause permanent damage, it is often ignored. The market is mainly driven by factors such as the rising prevalence of ischemia stroke cases, growing geriatric population, and increasing healthcare expenditure. However, the high cost of surgical procedures for the treatment of ischemic is likely to hinder the market growth.
Market Dynamics
The transient ischemic attack market is expected to exhibit exponential growth during the forecast period which is driven by all-rounder characteristics of the transient ischemic attack, increasing prevalence of chronic diseases such as cardiovascular diseases and cancer, and increase in the treatment of chronic diseases for the elderly population. It has been identified as one of the fastest emerging industries owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an excess of public companies. As per the survey carried out by American Heart Association Report 2015, more than 17.9 million deaths were recorded in the US due to cardiovascular disorder, and the death rate is expected to grow to more than 23.6 Million by 2030. Besides, increasing healthcare expenditure has fueled the growth of the market. However, the growth of the market is restrained by the side effects of drugs for strokes and strict regulations for manufacturing medical devices for the treatment of strokes.
Transient Ischemic Attack Market Size, by Diagnosis, 2016 and 2023 (USD Million) Â 
Source: MRFR Analysis
Segmentation
The transient ischemic attack has been segmented into diagnosis, treatment, age group, and end user. Based on the diagnosis, the market has been divided into imaging techniques and others. The imaging technique is further sub-segmented into computed tomography (CT) scan, carotid duplex scanning, magnetic resonance imaging, and echocardiography. The imaging technique segment accounted for a market value of USD 1004.4 Million in 2016. Based on treatment, the market has been segregated into surgery and drugs. The drugs segment is further sub-segmented into antithrombotic agents, antiplatelets, clopidogrel, aspirin, heparins, enoxaparin, dalteparin, fibrinolytic, and tenecteplase. By age groups, the market is further classified as  0–18 years, 19–40 years (Millennial), 41–60 years, and 60+ years. Based on end-user, the transient ischemic attack market has been bifurcated into hospitals & clinics, diagnostic centers, and research laboratories.
Key Players
The prominent players in the transient ischemic attack market are Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany).Â
Some of the key strategies followed by the players operating in the transient ischemic attack market were innovation, product development, acquisition, mergers, and expansion.
 Asia-Pacific Transient Ischemic Attack Market Share, By Country, 2016 (%)  
Source: MRFR Analysis
Regional Analysis
The transient ischemic attack market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the transient ischemic attack market during the forecast period. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market. People in this region are very health conscious, which has led to increasing healthcare expenditure in this region.
Europe accounted for the second-largest market for transient ischemic attack. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and the rising prevalence of cardiac disorders. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region. Japan held the most significant market share of 32.97 % in 2016.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
-
In February 2018, Merck & Co. Inc acquired Viralytics Limited. This acquisition expanded Merck’s immunology pipeline.
-
In January 2018, Abbott entered into a definitive merger agreement by acquiring Alere Inc., a diagnostic device and service provider, for USD 56.00 per common share in cash.
-
In October 2018, Stryker Corporation announced the acquisition of VEXIM, a French medical device company. This acquisition enabled Stryker Corporation to increase its revenue in the future.
-
In August 2017, Sanofi completed the acquisition of Protein Sciences. This acquisition was a strategic fit for Sanofi Pasteur’s for developing new manufacturing technologies.
-
In May 2017, Boston Scientific Corporation announced the acquisition of Symetis SA, to focus on minimally invasive transcatheter aortic valve implantation (TAVI) devices.
Market Segmentation
Transient Ischemic Attack Market, by Diagnosis
- Imaging Techniques
- Computed Tomography (CT) scan
- Carotid Duplex Scanning
- Magnetic Resonance Imaging
- Echocardiography      Â
Transient Ischemic Attack Market, by Treatment
- Surgery
- Drugs
- Antithrombotic agents
- Antiplatelets
- Clopidogrel
- Aspirin
- Heparins
- ENOXAPARIN
- DALTEPARIN
- Fibrinolytics
- Tenecteplase
Transient Ischemic Attack Market, by Age Groups
- 0–18 years
- 19–40 years (Millennial)
- 41–60 years
- 60+ years
Transient Ischemic Attack Market, by End-User
- Hospitals & Clinics
- Diagnostic Centers
- Research Laboratories
Transient Ischemic Attack Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Additional Companies
- LivaNova PLC
- EnteroMedics Inc.
- ElectroCore Medical LLC
- Cyberonics, Inc.
- NeuroMetrix, Inc.
- ImThera Medical
- Inspire Medical Systems, Inc.
- Nihon Kohden Corporation
- Electrical Geodesics Inc.
Intended Audience
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
-
Contract research organizations - Academic institutes and universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
